1921
Volume 87, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The immunogenicity and safety of three novel host-range vaccines containing deletions in the transmembrane domain of dengue virus serotype 2 (DV2) E glycoprotein were evaluated in African green monkeys. The shorter transmembrane domains are capable of functionally spanning an insect but not a mammalian cell membrane, resulting in production of viral mutants that have reduced infectivity in mammalian hosts but efficient growth in insect cells. Groups of four monkeys received one dose each of test vaccine candidate with no booster immunization. After immunization, levels of viremia produced by each vaccine were determined by infectious center assay. Vaccine recipient immune response to wild-type DV2 challenge was measured on Day 57 by enzyme-linked immunosorbent assay and plaque reduction neutralization test. Two vaccines, DV2ΔGVII and DV2G460P, generated neutralizing antibody in the range of 700–900 50% plaque reduction neutralization test units. All three vaccine strains decreased the length of viremia by at least two days. No safety concerns were identified.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2012.12-0004
2012-10-03
2017-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/87/4/743.html?itemId=/content/journals/10.4269/ajtmh.2012.12-0004&mimeType=html&fmt=ahah

References

  1. Henchal EA, Putnak JR, , 1990. The dengue viruses. Clin Microbiol Rev 3: 376396.[Crossref]
  2. Sideridis K, Canario D, Cunha BA, , 2003. Dengue fever: diagnostic importance of a camelback fever pattern. Heart Lung 32: 414418.[Crossref]
  3. Kurane I, , 2007. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 30: 329340.[Crossref]
  4. Edelman R, , 2005. Dengue and dengue vaccines. J Infect Dis 191: 650653.[Crossref]
  5. World Health Organization, 2009. Dengue and Dengue Haemorrhagic Fever. Geneva: World Health Organization.
  6. World Health Organization, 2009. Health Topics: Dengue. Geneva: World Health Organization.
  7. Halstead SB, Schlesinger RW, , 1980. Immunological parameters of togavirus disease syndromes. . The Togaviruses. New York, Academic Press, 107168.[Crossref]
  8. World Health Organization, 2012. Dengue/Dengue Haemorrhagic Fever. Geneva: World Health Organization.
  9. World Health Organization, 2012. Health Topics: Dengue. Geneva: World Health Organization.
  10. Wills BA, Oragui EE, Stephens AC, Daramola OA, Dung NM, Loan HT, Chau NV, Chambers M, Stepniewska K, Farrar JJ, Levin M, , 2002. Coagulation abnormalities in dengue hemorrhagic fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome. Clin Infect Dis 35: 277285.[Crossref]
  11. Clark DV, Mammen MP, Jr Nisalak A, Puthimethee V, Endy TP, , 2005. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg 72: 786791.
  12. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, , 2007. Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518528.[Crossref]
  13. Martina BE, Koraka P, Osterhaus AD, , 2009. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 22: 564581.[Crossref]
  14. Hernandez R, Lee H, Nelson C, Brown DT, , 2000. A single deletion in the membrane-proximal region of the Sindbis virus glycoprotein E2 endodomain blocks virus assembly. J Virol 74: 42204228.[Crossref]
  15. Hernandez R, Sinodis C, Horton M, Ferreira D, Yang C, Brown DT, , 2003. Deletions in the transmembrane domain of a sindbis virus glycoprotein alter virus infectivity, stability, and host range. J Virol 77: 1271012719.[Crossref]
  16. Whitehurst CB, Willis JH, Sinodis CN, Hernandez R, Brown DT, , 2006. Single and multiple deletions in the transmembrane domain of the Sindbis virus E2 glycoprotein identify a region critical for normal virus growth. Virology 347: 199207.[Crossref]
  17. Smith KM, Nanda K, Spears CJ, Ribeiro M, Vancini R, Piper A, Thomas GS, Thomas ME, Brown DT, Hernandez R, , 2011. Structural mutants of dengue virus 2 transmembrane domains exhibit host-range phenotype. Virol J 8: 289.[Crossref]
  18. Cologna R, Armstrong PM, Rico-Hesse R, , 2005. Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol 79: 853859.[Crossref]
  19. Schoepp RJ, Beaty BJ, Eckels KH, , 1991. Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation. Am J Trop Med Hyg 45: 202210.
  20. Smith KM, Nanda K, Spears CJ, Ribeiro M, Vancini R, Piper A, Thomas GS, Thomas ME, Brown DT, Hernandez R, , 2011. Structural mutants of dengue virus 2 transmembrane domains exhibit host-range phenotype. Virol J 8: 289.[Crossref]
  21. Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, Summers PL, Innis BL, Eckels KH, Hoke CH, Jr, 2003. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 69: 1723.
  22. Putnak RJ, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA, Seriwatana J, Cayphas S, Garcon N, Gheysen D, Kanesa-Thasan N, McDonell M, Humphreys T, Eckels KH, Prieels JP, Innis BL, , 2005. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23: 44424452.[Crossref]
  23. Bente DA, Rico-Hesse R, , 2006. Models of dengue virus infection. Drug Discov Today Dis Models 3: 97103.[Crossref]
  24. Martin J, Hermida L, Castro J, Lazo L, Martinez R, Gil L, Romero Y, Puente P, Zaragoza S, Cosme K, Guzman MG, Cardosa J, Guillen G, , 2009. Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: a potential model for vaccine testing. Microbiol Immunol 53: 216223.[Crossref]
  25. Martin J, Hermida L, Castro J, Romero Y, Cardosa J, Guillen G, , 2009. Viremia and the magnitude of the immune response upon infection of green monkeys with dengue virus type 2 are strain-dependent. Curr Microbiol 59: 579583.[Crossref]
  26. Ammerman NC, Beier-Sexton M, Azad AF, , 2008. Growth and maintenance of Vero cell lines. Curr Protoc Microbiol Nov: Appendix 4E.
  27. National Human Genome Research Institute. The Importance of the Vervet (African Green Monkey) as a Biomedical Model. Available at: http://www.genome.gov/pages/research/sequencing/seqproposals/thevervetmonkeybiomedicalmodel.pdf.
  28. Hernandez R, Sinodis C, Brown DT, , 2010. Sindbis virus: propagation, quantification, and storage. Curr Protoc Microbiol Feb: Chapter 15: Unit 15B.1.
  29. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapravati N, Gubler DJ, , 1997. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230: 300308.[Crossref]
  30. Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH, Jr, 2003. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 69: 1216.
  31. Halstead SB, Marchette NJ, , 2003. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 69: 511.
  32. Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W, , 2008. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg 79: 115122.
  33. Marchette NJ, Halstead SB, Falkler WA, Jr Stenhouse A, Nash D, , 1973. Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J Infect Dis 128: 2330.[Crossref]
  34. Halstead SB, Shotwell H, Casals J, , 1973. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 128: 714.[Crossref]
  35. Marchette NJ, Halstead SB, , 1973. Survival of dengue virus in post mortem samples of tissues from experimentally infected rhesus monkeys. Am J Trop Med Hyg 22: 242243.
  36. Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, Innis BL, Thomas SJ, Endy TP, , 2006. Protection of rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 193: 16581665.[Crossref]
  37. Simmons M, Burgess T, Lynch J, Putnak R, , 2009. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396: 280288.[Crossref]
  38. Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, Sadoff JC, Eckels KH, , 1996. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 174: 11761184.[Crossref]
  39. Cassell S, Edwards J, Brown DT, , 1984. Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus. J Virol 52: 857864.
  40. Riedel B, Brown DT, , 1977. Role of extracellular virus on the maintenance of the persistent infection induced in Aedes albopictus (mosquito) cells by Sindbis virus. J Virol 23: 554561.
  41. Edwards J, Mann E, Brown DT, , 1983. Conformational changes in Sindbis virus envelope proteins accompanying exposure to low pH. J Virol 45: 10901097.
  42. Edwards J, Brown DT, , 1991. Sindbis virus infection of a Chinese hamster ovary cell mutant defective in the acidification of endosomes. Virology 182: 2833.[Crossref]
  43. Roehrig JT, Hombach J, Barrett AD, , 2008. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21: 123132.[Crossref]
  44. Mathews DH, Sabina J, Zuker M, Turner DH, , 1999. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 288: 911940.[Crossref]
  45. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP, , 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74: 54775485.[Crossref]
  46. Freire MS, Marchevsky RS, Almeida LF, Yamamura AM, Caride EC, Brindeiro PA, Motta MC, Nogueira RM, Kubelka CF, Bonaldo MC, Galler R, , 2007. Wild dengue virus types 1, 2 and 3 viremia in rhesus monkeys. Mem Inst Oswaldo Cruz 102: 203208.[Crossref]
  47. Russell PK, Nisalak A, Sukhavachana P, Vivona S, , 1967. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99: 285290.
  48. Yun SI, Kim SY, Rice CM, Lee YM, , 2003. Development and application of a reverse genetics system for Japanese encephalitis virus. J Virol 77: 64506465.[Crossref]
  49. Schlesinger JJ, Brandriss MW, , 1981. Growth of 17D yellow fever virus in a macrophage-like cell line, U937: role of Fc and viral receptors in antibody-mediated infection. J Immunol 127: 659665.
  50. Innis BL, Eckels KH, Kraiselburd E, Dubois DR, Meadors GF, Gubler DJ, Burke DS, Bancroft WH, , 1988. Virulence of a live dengue virus vaccine candidate: a pssible new marker of dengue virus attenuation. J Infect Dis 158: 876880.[Crossref]
  51. Saluzzo JF, , 2003. Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis. Adv Virus Res 61: 419443.[Crossref]
  52. Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, Summers PL, Hoke CH, , 1994. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis 170: 14481455.[Crossref]
  53. Halstead SB, O'Rourke EJ, , 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146: 201217.[Crossref]
  54. Littaua R, Kurane I, Ennis FA, , 1990. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144: 31833186.
  55. Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, Gubler DJ, Kinney RM, , 2000. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74: 30203028.[Crossref]
  56. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr de Silva AM, , 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA.
  57. Bernardo L, Hermida L, Martin J, Alvarez M, Prado I, Lopez C, Martinez R, Rodriguez-Roche R, Zulueta A, Lazo L, Rosario D, Guillen G, Guzman MG, , 2008. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol 153: 849854.[Crossref]
  58. Bernardo L, Izquierdo A, Prado I, Rosario D, Alvarez M, Santana E, Castro J, Martinez R, Rodriguez R, Morier L, Guillen G, Guzman MG, , 2008. Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol 15: 439446.[Crossref]
  59. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW, , 2010. Dengue: a continuing global threat. Nat Rev Microbiol 8: S7S16.[Crossref]
  60. Hernandez R, Paredes A, , 2009. Sindbis virus as a model for studies of conformational changes in a metastable virus and the role of conformational changes in in vitro antibody neutralisation. Rev Med Virol 19: 257272.[Crossref]
  61. Hernandez R, Paredes A, Brown DT, , 2008. Sindbis virus conformational changes induced by a neutralizing anti-E1 monoclonal antibody. J Virol 82: 57505760.[Crossref]
  62. Irie T, Kawai A, , 2005. Further studies on the mechanism of rabies virus neutralization by a viral glycoprotein-specific monoclonal antibody, #1-46-12. Microbiol Immunol 49: 721731.[Crossref]
  63. Reading SA, Dimmock NJ, , 2007. Neutralization of animal virus infectivity by antibody. Arch Virol 152: 10471059.[Crossref]
  64. Patterson RM, Selkirk JK, Merrick BA, , 1995. Baculovirus and insect cell gene expression: review of baculovirus biotechnology. Environ Health Perspect 103: 756759.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2012.12-0004
Loading
/content/journals/10.4269/ajtmh.2012.12-0004
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 03 Jan 2012
  • Accepted : 06 Jun 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error